Imunon FY2025 net loss $14.5M; Phase 2 OS benefit 14.7 months

Imunon, Inc.

2026-Q1 EPS reported -$0.84 vs consensus -$1.13 ▲ beat (+25.8%)

Net loss for 2025 was $14.5M ($6.83/sh) vs $18.6M ($16.94/sh) in 2024; operating expenses down 23%.
Final Phase 2 OVATION 2 data show median OS improvement of 14.7 months (45.1 vs 30.4 months) with IMNN-001+SoC vs SoC alone.
Phase 3 OVATION 3 enrollment ahead of plan; first patient dosed in Q3 2025.
Cash and cash equivalents $8.8M as of Dec 31, 2025; $7M registered direct offering closed Dec 2025.
Strategic reorganization Feb 2026 to reduce expenses and focus on Phase 3 study.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Imunon, Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the year ended December 31, 2025

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-013816

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.